Health Care • Biotechnology: Pharmaceutical Preparations
$29.99 ▲ +0.60
(+2.04%)
MKT CAP: $1.12B • VOL: 321.1K
52W L $27 52W H $55
HROW // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $272.3M | $199.6M | $130.2M |
| YoY Revenue Growth % | +36.4% | +53.3% | — |
| Gross Profit | $204.4M | $150.4M | — |
| Gross Margin % | 75.1% | 75.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $30.5M | $8.8M | $431.0K |
| Operating Margin % | 11.2% | 4.4% | 0.3% |
| Net Income (GAAP) | -$5.1M | -$17.5M | -$24.4M |
| EBITDA (Normalized) | $31.2M | $10.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $43.9M | -$22.2M | $3.8M |
| Capital Expenditures (CapEx) | $887.0K | $1.6M | — |
| Free Cash Flow (FCF) | $43.0M | -$23.8M | $3.8M |
| FCF Margin % | 15.8% | -11.9% | 2.9% |
| Return on Invested Capital (ROIC %) | 95.0% | 31.1% | — |
| Cash & Short-Term Equivalents | $72.9M | $47.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $52.4M | $69.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR HROW.